Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
The little compound that could: how phenytoin changed drug discovery and development.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Memory rehabilitation for people with multiple sclerosis.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
FDA warns about seizures linked to MS drug
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
Receptos provides update on progress of lead product candidate RPC1063
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.

Pages